Abstract
Literature publications (up to September 2006) concerning the synthesis of ω-phosphinyl-α-amino acids and their development towards use as therapeutic agents are reviewed. General and asymmetric methodologies for the preparation of straight-chain examples are described, including AP3-7 modulators of glutamate-responsive excitatory amino acid (EAA) receptors (i.e. ionotropic NMDA-, and metabotropic GrpIII mGlu-receptors), and the glutamate synthetase inhibitor phosphinothricin. Focusing primarily on the development of methods for introducing phosphonate and aminocarboxylate functions to the appropriate scaffold, approaches to conformationally constrained ω-phosphinyl-α-amino acids are also investigated, along with their relevance to the development of therapeutic regimens towards neurodegenerative disorders.
Current Organic Chemistry
Title: ω -Phosphinyl-α -Amino Acids: Synthesis, and Development towards Use as Therapeutic Agents
Volume: 11 Issue: 18
Author(s): Nick J. Wardle, S. W. Annie Bligh and Harry R. Hudson
Affiliation:
Abstract: Literature publications (up to September 2006) concerning the synthesis of ω-phosphinyl-α-amino acids and their development towards use as therapeutic agents are reviewed. General and asymmetric methodologies for the preparation of straight-chain examples are described, including AP3-7 modulators of glutamate-responsive excitatory amino acid (EAA) receptors (i.e. ionotropic NMDA-, and metabotropic GrpIII mGlu-receptors), and the glutamate synthetase inhibitor phosphinothricin. Focusing primarily on the development of methods for introducing phosphonate and aminocarboxylate functions to the appropriate scaffold, approaches to conformationally constrained ω-phosphinyl-α-amino acids are also investigated, along with their relevance to the development of therapeutic regimens towards neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Wardle J. Nick, Annie Bligh W. S. and Hudson R. Harry, ω -Phosphinyl-α -Amino Acids: Synthesis, and Development towards Use as Therapeutic Agents, Current Organic Chemistry 2007; 11 (18) . https://dx.doi.org/10.2174/138527207783221200
DOI https://dx.doi.org/10.2174/138527207783221200 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
Call for Papers in Thematic Issues
Catalytic C-H bond activation as a tool for functionalization of heterocycles
The major topic is the functionalization of heterocycles through catalyzed C-H bond activation. The strategies based on C-H activation not only provide straightforward formation of C-C or C-X bonds but, more importantly, allow for the avoidance of pre-functionalization of one or two of the cross-coupling partners. The beneficial impact of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prediction of Gene Co-Expression by Quantifying Heterogeneous Features
Current Bioinformatics Targeting Protein-Protein Interactions in the Proteasome Super-Assemblies.
Current Topics in Medicinal Chemistry Novel Multifunctional Anti-Alzheimer Drugs with Various CNS Neurotransmitter Targets and Neuroprotective Moieties
Current Alzheimer Research The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism The Mitochondrial Unfolded Protein Response: Role in Cellular Homeostasis and Disease
Current Molecular Medicine Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine Novel Therapeutic Strategies in Major Depression: Focus on RNAi and Ketamine
Current Pharmaceutical Design Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Serotonin 5-HT<sub>4</sub> Receptors: A New Strategy for Developing Fast Acting Antidepressants?
Current Pharmaceutical Design Prion Protein Misfolding
Current Molecular Medicine CD14-Dependent Innate Immunity-Mediated Neuronal Damage in Vivo is Suppressed by NSAIDs and Ablation of a Prostaglandin E2 Receptor, EP2
Current Medicinal Chemistry - Central Nervous System Agents Conantokins Inhibitors of Ion Flow through the N-Methyl-D-Aspartate Receptor Channels
Current Drug Targets Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside
Current Neuropharmacology Human Tooth Germ Stem Cells Preserve Neuro-Protective Effects after Long-Term Cryo-Preservation
Current Neurovascular Research Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation
CNS & Neurological Disorders - Drug Targets Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives
CNS & Neurological Disorders - Drug Targets RNA Therapeutics Directed to the Non Coding Regions of APP mRNA, In Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl cysteine
Current Alzheimer Research